Achim AIGNER | University of Leipzig, Leipzig | Institute of Pharmacology, Pharmacy and Toxicology
Mitarbeiter des Rudolf-Boehm-Institutes
European Technology Platform on Nanomedicine
Analysis of cellular and molecular antitumor effects upon inhibition of SATB1 in glioblastoma cells
Biocompatibility and Efficacy of Oligomaltose-Grafted Poly(ethylene imine)s (OM-PEIs) for in Vivo Gene Delivery
Exploring the MIR143-UPAR Axis for the Inhibition of Human Prostate Cancer Cells In Vitro and In Vivo
Perspectives, issues and solutions in RNAi therapy: the expected and the less expected
Mitarbeiter des Rudolf-Boehm-Institutes
Mitarbeiter des Rudolf-Boehm-Institutes
Achim AIGNER | University of Leipzig, Leipzig | Institute of Pharmacology, Pharmacy and Toxicology
Multiple effects of the special ATâ•'rich binding protein 1 (SATB1) in colon carcinoma
Targeted CRM197-PEG-PEI/siRNA Complexes for Therapeutic RNAi in Glioblastoma
Mitarbeiter des Rudolf-Boehm-Institutes
Achim AIGNER | University of Leipzig, Leipzig | Institute of Pharmacology, Pharmacy and Toxicology
Achim AIGNER | University of Leipzig, Leipzig | Institute of Pharmacology, Pharmacy and Toxicology
Anti-tumor effects of fibroblast growth factor-binding protein (FGF-BP) knockdown in colon carcinoma – topic of research paper in Biological sciences. Download scholarly article PDF and read for free on CyberLeninka open science
Foresee Edebi sanatlar yelken achim aigner leipzig university germany Tren istasyonu ilgisiz yerine getirmek
Achim AIGNER | University of Leipzig, Leipzig | Institute of Pharmacology, Pharmacy and Toxicology
Achim AIGNER | University of Leipzig, Leipzig | Institute of Pharmacology, Pharmacy and Toxicology
Analysis of SATB1 in Head and Neck Squamous Cell Carcinoma
MedTech-2022 Conferences | MedTech -2022 | MedTech 2022 Events | Pharma Industry and MedTech | MedTech Conferences | MedTech Meetings | Pharma Industry and MedTech | | Pharma Industry and MedTech Congress
Silencing of Neuropilins and GIPC1 in pancreatic ductal adenocarcinoma exerts multiple cellular and molecular antitumor effects | Scientific Reports
PDF) The proto-oncogene Pim-1 is a target of miR-33a | Marshall Thomas - Academia.edu
